The Transdermal Advantage

Continuous Delivery
For optimum delivery profiles for up to 7 days

Improve Bioavailability
Avoid first-pass metabolism

Eliminate Peaks and Troughs
Enhance efficacy and decrease adverse events

Improve Tolerability

Improve Patient Compliance
With increased comfort and convenience
Cutting Edge
Transdermal Technology

Difficult product formulation requires creative solutions

Aveva’s Transdermal technology is based on extensive experience with a full range of adhesive systems, permeation enhancer technology, system designs, and transdermal process engineering for creative product development. The merging of this broad-base expertise allows for the creation of individualized systems suited for each new product.

To confront the overwhelming technical challenges faced in the transdermal industry, Aveva has created specialized new technologies, including:

- **Drug-in-adhesive technology for volatile drugs**
  Minimize volatile drug loss during processing

- **Unique polymer combinations for solubility of crystalline drugs**
  Specialized polymer/excipient combinations to maintain solubility of crystalline drugs

- **Unique multilayer designs for controlled delivery profiles**
  Systems that can produce specialized delivery profiles for up to 7 days

- **Specialized formulations and processing for labile molecules**
  Avoid thermal degradation during processing

- **Liquid systems for poorly soluble drugs and maximum delivery rates**
  Liquid or solution-based transdermal systems for “problem” drugs

In addition, Aveva continues to research a variety of new transdermal technologies which will likely expand the range of compounds compatible with elegant patch designs.

Merging Technologies

Aveva Drug Delivery Systems is part of Nitto Denko, a $4 billion global technology company with extensive expertise in polymers and adhesives, which have applications in a number of industries. Nitto Denko is a pioneer and third largest manufacturer of transdermal drug delivery systems in the world, and the number one in Japan with three of the most successfully produced transdermal patches.

The primary goal of Aveva’s Transdermal technology is to produce effective transdermal systems that are:

- Small
- Elegant
- Comfortable to Wear
- Easy to Use
- Cost Effective
Transdermal partnership geared for success

A Proven Strategy

Aveva Drug Delivery Systems has extensive resources to support fast product development, from feasibility through commercialization. Aveva Drug Delivery Systems (formerly Elan Transdermal Technologies) has become a leader in transdermal technology development, demonstrating success through commercialization. Aveva’s development strategy is facilitated by:

- Feasibility utilizing broad based technology.
- Extensive analytical support and equipment including analytical R&D.
- A validated in-vitro skin permeation model with proven success for a wide range of drugs.
- Completely scalable, pilot-scale R&D processing equipment dedicated to process studies, trials, and pilot clinical supplies.
- Proven scale up/technology transfer to large scale equipment.
- Commercial facilities capable of producing over 240 million patches per year.

Choosing the right partner to improve the chances of success.

Aveva DDS has the expertise to evaluate the transdermal feasibility of any drug candidate. Multiple transdermal formulations, considering molecular size, dosage and delivery demands, solubility, and stability can quickly be evaluated. In addition, existing transdermal candidates can be optimized for improved product characteristics. New transdermal technologies can be developed to meet product needs and implemented with proprietary engineering capabilities.

With its strong focus on development and established experience in all development phases, from formulation, scale-up, regulatory, clinical, QA/QC, and manufacturing, Aveva DDS is the ideal partner to bring your product to commercial success.

Aveva DDS has several products in late and early stages of development, including the Nicotine Transdermal System (marketed in the U.S.), as well as several generic and proprietary transdermal systems.
For more information contact:

AVEVA Drug Delivery Systems, Inc.
3250 Commerce Parkway
Miramar, FL 33025

Claudia Guidotti

Tel.: (954) 624-1359
Fax: (954) 430-3390

Website: www.avevadds.com